Business

Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide sales of products using the formulations and will be responsible for up to $65 million in expenses for Phase 3 development and … [Read more...] about Grifols licenses Aradigm’s inhaled ciprofloxacin formulations

According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis's triptan nasal sprays using its Intravail transmucosal absorption enhancers; the company got the first patent in September 2012. Clinical trials have demonstrated that … [Read more...] about Aegis gets second patent for intranasal formulations of triptans

The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled "Sustained release of anti-infective aminoglycosides," covers formulations of aminoglycosides, including amikacin, with Insmed's liposomal delivery platform, formulation methods, … [Read more...] about Insmed gets European patent for Arikace

Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA '081 bifunctional muscarinic antagonist-beta2 agonist monotherapy, and vilanterol monotherapy. Elan CEO Kelly Martin explained, “This transaction, upon closing, will immediately … [Read more...] about Elan makes billion dollar deal for inhaled drug royalites

Vectura has announced that it has partnered with Chinese pharmaceutical company Tianjin KingYork Group and Hong Kong private equity investor Zendex Bio Strategy to create Tianjin Kinnovata Pharmaceutical Company Limited ("Kinnovata"). The new company will develop, manufacture, and market inhaled drugs for asthma and COPD in Asia. Kinnovata will be an independent … [Read more...] about New joint venture in China to develop inhaled drugs

Alexza Pharmaceuticals and Teva Pharmaceuticals USA have announced that Teva will market Adasuve loxapine inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in the US. The FDA approved Adasuve in December 2012. Teva will pay Alexza $40 million up front, up to $195 million in milestone payments, and additional tiered … [Read more...] about Teva to market Alexza’s Adasuve loxapine inhalation powder in US

The 19 member companies of the Medicon Valley Inhalation Consortium (MVIC) have announced the creation of a single company called MVIC AB in order to simplify customer relationships with the organization. Orest Lastow of Zenit Design, who founded the consortium, will be CEO. MVIC AB has 2 GMP facilities and provides a full range of inhalation product services, … [Read more...] about Inhalation consortium announces formation of jointly-owned company

Israeli/American biotech company Andain Inc. says that it has developed an "innovative lipid-based drug delivery nano-particles capable of carrying hydrophilic and hydrophobic drugs to a targeted human organ with timely drug release capabilities" and announced that it has developed an inhalation solution for the treatment of COPD using the technology. The company … [Read more...] about Andain announces launch of inhaled nano-particle drug delivery technology